Transaction Details

Footnotes

Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. | Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. | On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. | On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019. | On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019. | On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). | On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). | On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. | Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date. | Options were fully vested at the grant date.